Position of a panel of international lung cancer experts on the approval decision for use of durvalumab in stage III non-small-cell lung cancer (NSCLC) by the Committee for Medicinal Products for Human Use (CHMP)

作者：Solange Peters, Urania G. Dafni, Michael Joseph Boyer, Dirk De Ruysscher, Corinne Faivre Finn, Enriqueta Felip, Pilar Garrido, Nicolas M Girard, Matthias Gückenberger, John B.A.G. Haanen, Cecile Le Pechoux, F. Mornex, Mahmut Özsahin, Luis G Paz-Ares, David Planchard, David Raben, Suresh S. Ramalingam, Martin Reck, Egbert Frederik Smit, R. Stahel, Albrecht Stenzinger, Charles Swanton, Stefania Vallone, Marina Chiara Garassino · 发表于：Annals of Oncology · 年份：2019 · DOI：10.1093/annonc/mdy553 · 被引用次数：76 · 研究领域：Lung Cancer Treatments and Mutations、Cancer Immunotherapy and Biomarkers、Lung Cancer Diagnosis and Treatment

The two recent publications of durvalumab [1.Antonia S.J. Villegas A. Daniel D. et al.Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer.N Engl J Med. 2017; 377: 1919-1929Crossref PubMed Scopus (2469) Google Scholar, 2.Antonia S.J. Villegas A. Daniel D. et al.Overall survival with durvalumab after chemoradiotherapy in stage III NSCLC.N Engl J Med. 2018; 379: 2342-2350Crossref PubMed Scopus (1607) Google Scholar] showing that consolidation immunotherapy with durvalumab following chemoradiotherapy (chemoRT) could significantly improve the outcome of patients with inoperable stage III NSCLC have given rise to high hopes among patients, clinicians, and lung cancer experts. No significant advances have been made in the treatment of stage III NSCLC patients for at least two decades. Stage III NSCLC represents 20–25% of NSCLC and worldwide approximately 500 000 patients are diagnosed every year. This stage includes either locally advanced primary tumors with infiltration of vital mediastinal organs or involvement of locoregional mediastinal lymph nodes. Over the past decade, concomitant chemotherapy and radiotherapy has remained the standard of care for unresectable stage III NSCLC, irrespective of histological subtype or molecular characteristics. Currently, only 15–30% of patients are alive five years after chemoRT, and this figure remains largely unchanged despite multiple phase III randomized trials integrating surgery, higher radiation dose or induction/...